Kalaris Therapeutics (KLRS) CAO sells stock and gets large option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kalaris Therapeutics Chief Accounting Officer Brett R. Hagen reported an open-market sale of 1,915 shares of common stock at $6.72 per share, leaving no directly held common shares after the transaction. On the prior day, he received a grant of stock options for 60,800 shares of common stock at an exercise price of $6.81 per share, expiring on March 18, 2036. According to the grant terms, 25% of the underlying shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service. A footnote clarifies that a previous filing overstated his beneficial ownership by 10 shares, from 1,925 to 1,915, and this has now been corrected.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,915 shares ($12,869)
Net Sell
2 txns
Insider
Hagen Brett R
Role
Chief Accounting Officer
Sold
1,915 shs ($13K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,915 | $6.72 | $13K |
| Grant/Award | Stock Option (Right to Buy) | 60,800 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 0 shares (Direct);
Stock Option (Right to Buy) — 60,800 shares (Direct)
Footnotes (1)
- Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly. The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
